DHL Group completed the acquisition of CRYOPDP from Cryoport.

DHL Group, a global logistics provider, completed the acquisition of CRYOPDP, a specialty courier focused on clinical trials, biopharma, and cell and gene therapies, from Cryoport, a supply chain solutions provider for the life sciences with an emphasis on cell and gene therapies. Financial terms were not disclosed. "The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities," Oscar de Bok, DHL Supply Chain CEO.